Premium
Failure of SKF 38393‐A to relieve parkinsonian symptoms induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the marmoset
Author(s) -
Close S.P.,
Marriott A.S.,
Pay Sharon
Publication year - 1985
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1985.tb08863.x
Subject(s) - mptp , benserazide , marmoset , agonist , parkinson's disease , medicine , pharmacology , levodopa , neuroscience , receptor , psychology , disease , biology , paleontology
Chronic administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets. These symptoms were reduced by L‐DOPA plus benserazide but the putative D 1 ‐preceptor agonist SKF 38393‐A did not affect tremor and increased the bradykinesia. Neither treatment affected behaviour in normal marmosets. It is suggested that D 1 ‐receptor agonists are unlikely to be effective in the treatment of Parkinson's disease.